Dr. Dangond is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
27 Dale Dr
Chatham, NJ 07928Phone+1 973-210-7327
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1990 - 1994
Columbia Saint Luke's Medical CenterResidency, Internal Medicine, 1988 - 1990
Pontifical Xavierian UniversityClass of 1987
Certifications & Licensure
MA State Medical License 1992 - 2025
NJ State Medical License 2007 - 2025- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 1 citationsTwenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn
Neurology and Therapy. 2024-04-01 - The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.Patrick Vermersch, Andrew Galazka, Fernando Dangond, Doris Damian, Schiffon L Wong
Neurodegenerative Disease Management. 2022-12-01 - 8 citationsDetermination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.Orestis Papasouliotis, David Mitchell, Pascal Girard, Fernando Dangond, Martin Dyroff
Clinical and Translational Science. 2022-12-01
Press Mentions
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of SafetyJune 24th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
